Concepedia

Publication | Open Access

Real-life efficacy and safety of Ustekinumab as second- or third-line therapy in Crohn's disease: results from a large Italian cohort study.

DOIFull Paper Access

15

Citations

0

References

2021

Year

Antonio Tursi, Giammarco Mocci, Alessandro Cuomo, Leonardo Allegretta, Giovanni Aragona, Rocchina Colucci, Nicola Della Valle, Antonio Ferronato, Giacomo Forti, Francesca Maria Gaiani,
PubMed

Abstract

UST seemed to be really effective and safe in CD patients unresponsive to other biologic treatments, especially when used as second-line treatment.